Report
FLASH - Pherecydes Pharma - Acheter - Obj. 5.50€
Pherecydes met fin à ses difficultés de financement en se rapprochant de la biotech française Erytech Pharma dont la trésorerie solide va permettre de créer un acteur majeur de phagothérapie en Europe. La société pérennise ainsi tous ses programmes cliniques et va même procéder à une extension de PhagoDAIR.
Underlying
Pherecydes Pharma
Provider
Portzamparc Sponsored
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Mohamed Kaabouni
Other Reports on these Companies
Other Reports from Portzamparc Sponsored
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.